Emerging therapies for acute coronary syndromes

about

The Impact of Thrombocytopenia on Outcome in Patients with Acute Coronary Syndromes: A Single Center Retrospective Study.

P2860

Q33427072-41EC7B96-D862-4852-9657-FC55A2FA9620

P2860

Emerging therapies for acute coronary syndromes

Item

http://www.wikidata.org/entity/Q37949587

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging therapies for acute coronary syndromes

@en

Emerging therapies for acute coronary syndromes.

@nl

type

Item

label

Emerging therapies for acute coronary syndromes

@en

Emerging therapies for acute coronary syndromes.

@nl

prefLabel

Emerging therapies for acute coronary syndromes

@en

Emerging therapies for acute coronary syndromes.

@nl

P1476

Emerging therapies for acute coronary syndromes

@en

P2093

Robert L Wilensky

http://www.w3.org/2001/XMLSchema#string

Scott M Lilly

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2011.00061

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51746615

http://www.w3.org/2001/XMLSchema#string

P698

22028691

http://www.w3.org/2001/XMLSchema#string

P932

3199568

http://www.w3.org/2001/XMLSchema#string

Emerging therapies for acute coronary syndromes

about

P2860

P2860

Emerging therapies for acute coronary syndromes

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932